Bajaj Healthcare Limited announced its financial results for the quarter and nine months ended December 31, 2025. For the third quarter of FY26, the company reported a significant 31.3% year-on-year increase in Revenue from Operations, reaching ₹1,612.2 crore (₹1612.2 million), compared to ₹1,227.9 crore in Q3 FY25. EBITDA also saw a substantial rise of 34.6% to ₹323.3 crore (₹323.3 million) from ₹240.1 crore in the prior year's quarter. Profit After Tax (PAT) from Continuing Operations grew by 7.6% to ₹161.0 crore (₹161.0 million), though the PAT margin decreased to 9.9% from 12.0%. For the nine months ended December 31, 2025, Revenue from Operations increased by 18.0% to ₹4,579.7 crore (₹4579.7 million), with PAT from Continuing Operations up by 30.0% to ₹407.2 crore (₹407.2 million). The company highlighted strong export momentum, particularly in API exports, which more than doubled year-on-year, contributing significantly to the revenue growth. The domestic API business grew by 15.3%. The formulations business also showed growth, increasing by 6.8%. Key business highlights include receiving CDSCO approval for Phase III clinical trials of Suvorexant Tablets, becoming the first Indian company to achieve this. The company also successfully launched Magnesium L-Threonate (Magtein) in India through a collaboration with Threotech LLC. Additionally, Bajaj Healthcare filed 9 Drug Master Files (DMFs) during the quarter, bringing the cumulative DMF filings to 69. Cumulative CEP filings stand at ten, with eight approved and two under review. Mr. Anil Jain, Managing Director, commented that the results highlight the resilience of operations and disciplined execution, driven by strong API export growth and steady volume growth in the domestic API business. He also noted the increasing contribution from the formulations business and the traction in the CDSCO business. The company continues to advance its CNS portfolio with ongoing trials for Cenobamate and the launch of Magtein. The focus remains on expanding presence in regulated markets and aligning the pipeline with high-value therapeutic areas.